Evidence map›Paper›PMID 31270600›Full record

ArticleJournal of cancer research and clinical oncology2019

Prognostic impact of PIK3CA protein expression in triple negative breast cancer and its subtypes.

C Elfgen, K Reeve, L Moskovszky, U Güth, V Bjelic-Radisic, M Fleisch, C Tausch, Z Varga

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed, 2 pooled it
1.9field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 2 syntheses or guidelines pooled it, 29 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

C ElfgenBreast Center Zurich, Seefeldstrasse 214, 8008, Zurich, Switzerland. c.elfgen@brust-zentrum.ch.ORCID http://orcid.org/0000-0001-6092-6612
K ReeveEpidemiology, Biostatistics and Prevention Institute, Biostatistics Department, University of Zurich, Zurich, Switzerland.
L MoskovszkyInstitute of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.
U GüthBreast Center Zurich, Seefeldstrasse 214, 8008, Zurich, Switzerland.
V Bjelic-RadisicDepartment for Gynecology and Obstetrics, Helios Hospital Wuppertal, University of Witten, Witten/Herdecke, Germany.
M FleischDepartment for Gynecology and Obstetrics, Helios Hospital Wuppertal, University of Witten, Witten/Herdecke, Germany.
C TauschBreast Center Zurich, Seefeldstrasse 214, 8008, Zurich, Switzerland.
Z VargaInstitute of Pathology and Molecular Pathology, University Hospital of Zurich, Zurich, Switzerland.
Witten/Herdecke University · DEBreast Center · CHUniversity Hospital of Zurich · CHUniversity of Zurich · CH

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTriple negative breast cancer (TNBC) harbors a heterogeneous group of carcinomas with poor prognosis and high genetic variability. As a potential aim for targeted therapy, genetic mutations leading to an activation of the phosphoinositide 3-kinase pathway in a catalytic subunit (PIK3CA) in breast cancer have been analyzed currently. Little is known about the clinical impact and prognostic or predictive value of this marker in TNBC subtypes.

methodsSamples from 119 TNBC cases were submitted to immunohistochemical PIK3CA protein expression analysis and scored semi-quantitatively as negative, weak (1 +), or strongly expressed (2 +). Expression scores were correlated to patient's characteristics, imaging features, and TNBC subtypes. TNBC subtypes were categorized into four subtypes: basal like, mesenchymal like, luminal androgen receptor (LAR), and immunomodulatory.

resultsWe did not observe differences in clinical aspects and imaging features between TNBC with and without PIK3CA expression. PIK3CA expression was in general higher in the LAR subtype. The disease-free survival and overall survival were significantly better in TNBC with PIK3CA protein expression, independent of TNBC subtypes.

conclusionDespite conflicting results in the literature, our study clearly shows a better outcome of PIK3CA-expressing TNBC, independent of TNBC subtypes. PIK3CA expression in TNBC is not associated with specific clinical or diagnostic features. Further molecular studies and meta-analysis are warranted to clarify the prognostic and predictive role of PIK3CA protein expression.

Indexed as

AdultAgedBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesFemaleHumansImmunohistochemistryMiddle AgedPredictive Value of TestsPrognosisSurvival AnalysisTriple Negative Breast NeoplasmsBiomarkers, TumorClass I Phosphatidylinositol 3-KinasesPIK3CA protein, humanBreast cancer subtypesImaging featuresPI3K pathwayPIK3CA protein expressionTriple negative breast cancer

Identifiers

PMID31270600
PMCPMC11810235
OpenAlexW2954764000

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.